Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Leukemia

  Free Subscription


Articles published in Leuk Res

Retrieve available abstracts of 247 articles:
HTML format



Single Articles


    March 2024
  1. GARCIA-MANERO G, Kazmierczak M, Wierzbowska A, Fong CY, et al
    Pracinostat combined with azacitidine in newly diagnosed adult acute myeloid leukemia (AML) patients unfit for standard induction chemotherapy: PRIMULA phase III study.
    Leuk Res. 2024 Mar 12:107480. doi: 10.1016/j.leukres.2024.107480.
    PubMed     Abstract available


  2. WAN CL, Huang YH, Huang SM, Xu YL, et al
    Investigations of the prognostic value of RUNX1 mutation in acute myeloid leukemia patients: Data from a real-world study.
    Leuk Res. 2024;139:107483.
    PubMed     Abstract available


  3. PAN L, Li Y, Gao H, Lai X, et al
    Clinical features and management of germline CEBPA-mutated carriers.
    Leuk Res. 2024;138:107453.
    PubMed     Abstract available


  4. SIDI Y, Dong C, Wu Y, Faller DV, et al
    A critical evaluation of the EFS endpoint in AML: Does induction treatment failure timing have a profound impact on study design and results?
    Leuk Res. 2024;138:107465.
    PubMed     Abstract available


    February 2024
  5. BOURNE G, Diebold K, Espinoza-Gutarra M, Al-Kadhimi Z, et al
    Addition of single dose gemtuzumab ozogamicin to intensive induction chemotherapy in core-binding factor acute myeloid leukemia.
    Leuk Res. 2024;139:107467.
    PubMed     Abstract available


  6. ZHONG S, Kurish H, Walchack R, Li H, et al
    Efficacy and safety of mitoxantrone, etoposide, and cytarabine for treatment of relapsed or refractory acute myeloid leukemia.
    Leuk Res. 2024;139:107468.
    PubMed     Abstract available


  7. OSMAN AEG, Rets A, Patel AB
    KRAS mutations, autoimmunity and female sex in chronic myelomonocytic leukemia.
    Leuk Res. 2024;138:107466.
    PubMed    


  8. SANCHEZ-PETITTO G, Goloubeva OG, Masur J, Childress J, et al
    Clinical outcomes of patients with acute myeloid leukemia and cardiovascular disease.
    Leuk Res. 2024;138:107456.
    PubMed     Abstract available


  9. SUDO H, Tonoyama Y, Ikebe E, Hasegawa H, et al
    Proteomic analysis of adult T-cell leukemia/lymphoma: A biomarker identification strategy based on preparation and in-solution digestion methods of total proteins.
    Leuk Res. 2024;138:107454.
    PubMed     Abstract available


  10. GOULART H, Sastow D, Moshier E, Martin L, et al
    Systematic review and meta-analysis evaluating clinical outcomes in adult acute myeloid leukemia patients with central nervous system involvement.
    Leuk Res. 2024;137:107452.
    PubMed     Abstract available


  11. ELGHETANY MT, Patnaik MM, Khoury JD
    Myelodysplastic neoplasms evolving from inherited bone marrow failure syndromes / germline predisposition syndromes: Back under the microscope.
    Leuk Res. 2024;137:107441.
    PubMed     Abstract available


  12. RAMOS-CILLAN S, Lainez-Gonzalez D, Solan L, Blas C, et al
    When the devil is in the details: Similarities and differences between WHO and ICC classifications of AML.
    Leuk Res. 2024;137:107440.
    PubMed    


    January 2024
  13. BOUCHER L, Rozalska L, Sorel N, Olivier G, et al
    Emergence of secondary fusions in chronic myeloid leukemia as a driver of tyrosine kinase inhibitor resistance and blast crisis transformation.
    Leuk Res. 2024;137:107439.
    PubMed    


  14. OH I, Hatano K, Ikeda T, Toda Y, et al
    Phase 2 trial of induction with dasatinib and consolidation with hyper-CVAD plus dasatinib followed by allografting for Ph-positive acute lymphoblastic leukemia in adults.
    Leuk Res. 2024;137:107438.
    PubMed    


  15. DIDI I, Alliot JM, Dumas PY, Vergez F, et al
    Artificial intelligence-based prediction models for acute myeloid leukemia using real-life data: A DATAML registry study.
    Leuk Res. 2024;136:107437.
    PubMed     Abstract available


  16. KLINK AJ, Gajra A, Knoth RL, Marshall L, et al
    Corrigendum to "Real-world clinical outcomes with enasidenib in relapsed or refractory acute myeloid leukemia" [Leuk. Res. (2022) 106946].
    Leuk Res. 2024 Jan 9:107430. doi: 10.1016/j.leukres.2023.107430.
    PubMed    


  17. KUSNE Y, Lasho T, Finke C, Patnaik MM, et al
    VEXAS syndrome in a patient with DDX41 germline predisposition syndrome.
    Leuk Res. 2024;136:107432.
    PubMed    


  18. KHANNA V, Lu R, Kumar J, Molina A, et al
    The clinical, molecular, and prognostic features of the 2022 WHO and ICC classification systems for myelodysplastic neoplasms.
    Leuk Res. 2024;136:107433.
    PubMed     Abstract available


    December 2023
  19. NOTARANTONIO AB, Roth-Guepin G, Bonmati C, Divoux M, et al
    A new sequential conditioning regimen based on CPX- 351/Vyxeos ("Vyx-Seq") in patients with higher risk myelodysplastic syndromes.
    Leuk Res. 2023;135:107405.
    PubMed    


    November 2023
  20. ASHBY M, Fleming S, Teh TC, Tiong IS, et al
    Low-intensity venetoclax-based salvage as a bridge to allogeneic stem cell transplant in patients with acute myeloid leukemia failing conventional intensive chemotherapy.
    Leuk Res. 2023;136:107429.
    PubMed    


  21. URBINO I, Secreto C, Apolito V, Olivi M, et al
    Sorafenib in combination with intensive chemotherapy for relapsed or refractory FLT3-ITD positive acute myeloid leukemia: A two centers experience.
    Leuk Res. 2023 Nov 18:107421. doi: 10.1016/j.leukres.2023.107421.
    PubMed    


  22. ZHAO D, Zhou Q, Zarif M, Eladl E, et al
    AML with CEBPA mutations: A comparison of ICC and WHO-HAEM5 criteria in patients with 20% or more blasts.
    Leuk Res. 2023;134:107376.
    PubMed     Abstract available


    October 2023
  23. RAVINDRA A, Acharya L, Loeffler B, Mott S, et al
    Venetoclax-based therapy in treatment-naive and relapsed/refractory acute myeloid leukemia.
    Leuk Res. 2023;135:107407.
    PubMed     Abstract available


  24. ANSARI F, Behfar M, Jafari L, Mohseni R, et al
    A comprehensive comparison between TBI vs non-TBI-based conditioning regimen in pediatric patients with acute lymphoblastic leukemia: A systematic review and meta-analysis.
    Leuk Res. 2023;135:107416.
    PubMed     Abstract available


  25. ZHANG F, Du H, Hu C, Song Y, et al
    A new prognostic risk model for acute myeloid leukemia patients based on telomere-related genes.
    Leuk Res. 2023;135:107404.
    PubMed     Abstract available


  26. SHERBAN A, Fredman D, Shimony S, Yeshurun M, et al
    Safety and efficacy of FLAG-Ida-based therapy combined with venetoclax for the treatment for newly diagnosed and relapsed/refractory patients with AML - A systematic review.
    Leuk Res. 2023;133:107368.
    PubMed     Abstract available


    September 2023
  27. JIMENEZ-VICENTE C, Martinez-Roca A, Pomares H, Castano-Diez S, et al
    Venetoclax with hypomethylating agents might lead to eradication of measurable residual disease (MRD) persisting after intensive chemotherapy in acute myeloid leukemia (AML) patients with mutated NPM1 and rearranged CBF.
    Leuk Res. 2023;135:107403.
    PubMed    


  28. JAMY OH, Kasner M, Wall S, Ingram S, et al
    Integrating electronic geriatric assessment and frailty screening for adults with acute myeloid leukemia to drive personalized treatment decisions.
    Leuk Res. 2023;134:107393.
    PubMed     Abstract available


  29. GURNEY M, Greipp PT, Gliem T, Knudson R, et al
    TET2 somatic copy number alterations and allelic imbalances in chronic myelomonocytic leukemia.
    Leuk Res. 2023;134:107391.
    PubMed    


  30. SINGH C, Karunakaran P, Yanamandra U, Jindal N, et al
    Factors associated with thrombo-hemorrhagic deaths in patients with Acute Promyelocytic leukemia treated with Arsenic Trioxide and all-trans retinoic acid.
    Leuk Res. 2023;134:107392.
    PubMed     Abstract available


  31. PATEL SA, Bello E, Wilks A, Gerber JM, et al
    Harnessing autologous immune effector mechanisms in acute myeloid leukemia: 2023 update of trials and tribulations.
    Leuk Res. 2023;134:107388.
    PubMed     Abstract available


  32. HIRT CK, Padmanabha N, Michaels PD
    Cohesin complex mutations in myeloid neoplasms are enriched for SRSF2, RUNX1, TET2, and NRAS co-mutations and morphologic dysplasia.
    Leuk Res. 2023;132:107357.
    PubMed    


  33. BRANDWEIN JM, Ebeling K, Ding L, Liew E, et al
    Changing frontline AML treatment patterns from 2013 to 2022.
    Leuk Res. 2023;132:107354.
    PubMed     Abstract available


  34. XIE W, Wang Z, Guo X, Guan H, et al
    MiR-409-3p regulates the proliferation and apoptosis of THP-1 through targeting Rab10.
    Leuk Res. 2023;132:107350.
    PubMed     Abstract available


    August 2023
  35. DE LA GARZA-SALAZAR F, Colunga-Pedraza PR, Gomez-Almaguer D, Garcia-Zarate VA, et al
    Low dose venetoclax plus itraconazole outpatient induction in newly diagnosed acute myeloid leukemia: A phase 2 study.
    Leuk Res. 2023;133:107373.
    PubMed     Abstract available


  36. KHADADAH FM, Cerquozzi S, Olney HJ, Fraga C, et al
    Canadian real-world experience of asciminib treatment in heavily pre-treated chronic myeloid leukemia (CML) patients who failed multiple lines of tyrosine kinase inhibitor (TKI) therapy.
    Leuk Res. 2023;133:107374.
    PubMed     Abstract available


  37. OWEN C, Eisinga S, Banerji V, Johnson N, et al
    Canadian evidence-based guideline for treatment of relapsed/refractory chronic lymphocytic leukemia.
    Leuk Res. 2023;133:107372.
    PubMed     Abstract available


  38. BOULIGNY IM, Murray G, Ho T, Doyel M, et al
    Abbreviated venetoclax with decitabine or azacitidine in acute myeloid leukemia.
    Leuk Res. 2023;134:107370.
    PubMed    


  39. ZHAO ZY, Tang N, Lin LE
    A rare BCR-ABL1 transcript in chronic myeloid leukemia: Case report and literature review.
    Leuk Res. 2023;133:107369.
    PubMed     Abstract available


  40. BHATTACHARJEE U, Jandial A, Singh C, Lekshmon KS, et al
    Pregnancy and long-term outcomes of female patients with chronic myeloid leukemia on tyrosine kinase inhibitors who experienced unplanned pregnancies.
    Leuk Res. 2023;133:107367.
    PubMed     Abstract available


  41. JAIN T, Ware AD, Dalton WB, Pasca S, et al
    Co-occurring mutations in ASXL1, SRSF2, and SETBP1 define a subset of myelodysplastic/ myeloproliferative neoplasm with neutrophilia.
    Leuk Res. 2023;131:107345.
    PubMed     Abstract available


  42. HASSAN HT
    Antibody-drug conjugate [ADC] treatment of leukaemia.
    Leuk Res. 2023;131:107078.
    PubMed     Abstract available


    July 2023
  43. STAHL M, Giblin G, Liu Y, Winer ES, et al
    Incidence and predictors of anthracycline-related left ventricular dysfunction in acute myeloid leukemia.
    Leuk Res. 2023;132:107351.
    PubMed     Abstract available


  44. BRUNNER AM, Huggar D, Copher R, Zhou ZY, et al
    Economic burden during remission and after relapse among older patients with newly diagnosed acute myeloid leukemia without hematopoietic stem cell transplant: A retrospective study using the SEER-Medicare database.
    Leuk Res. 2023;132:107353.
    PubMed     Abstract available


  45. HEGER JM, Boll B, Naendrup JH, Simon F, et al
    Hyperleukocytosis in patients with acute myeloid leukemia admitted to the intensive care unit: a single-center retrospective analysis.
    Leuk Res. 2023;132:107352.
    PubMed     Abstract available


  46. DENG X, Zeng Y, Qiu X, Zhong M, et al
    CRIP1 supports the growth and migration of AML-M5 subtype cells by activating Wnt/beta-catenin pathway.
    Leuk Res. 2023;130:107312.
    PubMed     Abstract available


  47. KIRTEK T, Chen W, Laczko D, Bagg A, et al
    Acute leukemias with complex karyotype show a similarly poor outcome independent of mixed, myeloid or lymphoblastic immunophenotype: A study from the Bone Marrow Pathology Group.
    Leuk Res. 2023;130:107309.
    PubMed     Abstract available


    June 2023
  48. RATAJCZAK B, Przybylowicz-Chalecka A, Czerwinska-Rybak J, Kandula Z, et al
    The presence of additional cytogenetic aberrations in chronic myeloid leukemia cells at the time of diagnosis or their appearance on tyrosine kinase inhibitor therapy predicts the imatinib treatment failure.
    Leuk Res. 2023;132:107349.
    PubMed     Abstract available


  49. SHAIKH MR, Singh B, Halder R, Singh R, et al
    FLAG based v/s Standard 3 + 7 induction therapy in treatment naive Acute Myeloid Leukemia: Time to think "beyond anthracyclines".
    Leuk Res. 2023;132:107346.
    PubMed     Abstract available


  50. GUARANA M, Nucci M
    Should patients with acute myeloid leukemia treated with venetoclax-based regimens receive antifungal prophylaxis?
    Leuk Res. 2023;131:107341.
    PubMed     Abstract available


  51. MOORE JE, Bloom PC, Chu CC, Bruno JE, et al
    Rituximab induced cytokine release with high serum IP-10 (CXCL10) concentrations is associated with infusion reactions.
    Leuk Res. 2023;129:107072.
    PubMed     Abstract available


    May 2023
  52. KHANNA V, Azenkot T, Liu SQ, Gilbert J, et al
    Outcomes with molecularly targeted agents as salvage therapy following frontline venetoclax + hypomethylating agent in adults with acute myeloid leukemia: A multicenter retrospective analysis.
    Leuk Res. 2023;131:107331.
    PubMed    


  53. ILLANGESWARAN RSS, Jebanesan DZP, Sivakumar KK, Vidhyadharan RT, et al
    Corrigendum to "Chemotherapeutic drugs elicit stemness and metabolic alteration to mediate acquired drug-resistant phenotype in acute myeloid leukemia cell lines" [Leukemia Res. 128, 107054].
    Leuk Res. 2023 May 29:107329. doi: 10.1016/j.leukres.2023.107329.
    PubMed    


  54. BADE R, Banaszak LG, Osman F, Cabral P, et al
    Neighborhood disadvantage, insurance status, and molecular profiling of patients with acute myeloid leukemia.
    Leuk Res. 2023;131:107326.
    PubMed     Abstract available


  55. MARTINEZ-CASTILLO M, Gomez-Romero L, Tovar H, Olarte-Carrillo I, et al
    Genetic alterations in the BCR-ABL1 fusion gene related to imatinib resistance in chronic myeloid leukemia.
    Leuk Res. 2023;131:107325.
    PubMed     Abstract available


  56. SALAMA H, Eldadah S, Omer MH, Alhejazi A, et al
    Comparison of a modified pediatric protocol versus a hyper-CVAD protocol in adolescents and young adults with Philadelphia-negative acute lymphoblastic leukemia: A multicenter retrospective analysis.
    Leuk Res. 2023;130:107316.
    PubMed     Abstract available


  57. WU X, Thisdelle J, Hou S, Fajardo-Despaigne JE, et al
    Elevated expression of interleukin 16 in chronic lymphocytic leukemia is associated with disease burden and abnormal immune microenvironment.
    Leuk Res. 2023;131:107315.
    PubMed     Abstract available


  58. OYA S, Ozawa H, Maehiro Y, Nakamura T, et al
    Alternating venetoclax/azacytidine and FLT3 inhibitor treatment for NPM1- and FLT3-mutated acute myeloid leukemia.
    Leuk Res. 2023;130:107313.
    PubMed    


  59. ATCHLEY E, Weis TM, Derkach A, Galera PK, et al
    Outcomes with high dose cytarabine and mitoxantrone induction for adults with mixed phenotype acute leukemia.
    Leuk Res. 2023;130:107311.
    PubMed     Abstract available


  60. WANG Y, Liu H, Wang H, Wu Y, et al
    Enhancing morphological analysis of peripheral blood cells in chronic lymphocytic leukemia with an artificial intelligence-based tool.
    Leuk Res. 2023;130:107310.
    PubMed     Abstract available


  61. BALSAT M, Alcazer V, Etienne G, Huguet F, et al
    First-line second generation tyrosine kinase inhibitors in patients with newly diagnosed accelerated phase chronic myeloid leukemia.
    Leuk Res. 2023;130:107308.
    PubMed     Abstract available


  62. EDMUND J, Thaliath LJ, Meleveedu K
    Acute myeloid leukemia in the medically unfit elderly patients.
    Leuk Res. 2023;130:107306.
    PubMed     Abstract available


  63. ARCHIBALD WJ, Baran AM, Williams AM, Salloum RM, et al
    The role of splenectomy in management of splenic B-cell lymphomas.
    Leuk Res. 2023;128:107053.
    PubMed     Abstract available


  64. SUN X, Bai Y, Li M, Li W, et al
    Differential effects of recombinant human thrombopoietin on clinical outcomes in CD7-positive and CD7-negative acute myeloid leukaemia.
    Leuk Res. 2023;128:107034.
    PubMed     Abstract available


    April 2023
  65. TINAJERO J, Koller P, Ali H
    Ponatinib, asciminib and inotuzumab ozogamicin: A novel drug combination in acute lymphoblastic leukemia.
    Leuk Res. 2023;129:107299.
    PubMed    


  66. AIMAN W, Ali MA, Basit MA, Omar Z, et al
    Efficacy and tolerability of isocitrate dehydrogenase inhibitors in patients with acute myeloid leukemia: A systematic review of clinical trials.
    Leuk Res. 2023;129:107077.
    PubMed     Abstract available


  67. WILDE L, Porazzi P, Trotta R, De Dominici M, et al
    A phase I study of the combination of palbociclib and dexamethasone for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia.
    Leuk Res. 2023;129:107075.
    PubMed     Abstract available


  68. OWEN C, Banerji V, Johnson N, Gerrie A, et al
    Corrigendum to "Canadian evidence-based guideline for frontline treatment of chronic lymphocytic leukemia: 2022 update" [Leukemia Research 125 (2023) 107016].
    Leuk Res. 2023 Apr 3:107073. doi: 10.1016/j.leukres.2023.107073.
    PubMed    


  69. JINDRA P, Karas M, Lysak D, Sramek J, et al
    Determinants of refined GvHD-free, relapse-free survival after reduced-intensity allogeneic hematopoietic cell transplantation in older patients with myeloid malignancies.
    Leuk Res. 2023;127:107052.
    PubMed     Abstract available


  70. MIRET M, Anderson A, Hindocha P, Cirneanu L, et al
    Incidence of second primary malignancies in relapsed/refractory B-cell non-Hodgkin's lymphoma patients in England.
    Leuk Res. 2023;127:107042.
    PubMed     Abstract available


  71. KIRKIZLAR TA, Kirkizlar O, Demirci U, Umut A, et al
    Incidence and predisposing factors of infection in patients treated with hypomethylating agents.
    Leuk Res. 2023;127:107043.
    PubMed     Abstract available


    March 2023
  72. YI ES, Baek HJ, Ju HY, Kim SK, et al
    Response to chemotherapy in juvenile myelomonocytic leukemia and its clinical implications for survival: A retrospective registry-based study of the Korean Pediatric Hematology-Oncology Group.
    Leuk Res. 2023;129:107070.
    PubMed     Abstract available


  73. DELIA M, Gagliardi VP, Carluccio P, Attolico I, et al
    Long term follow-up of refractory/relapsed acute myeloid leukemia patients treated with the FLAG-Ida regimen as bridge therapy to allotransplantation: 10-year results from a single centre experience.
    Leuk Res. 2023;129:107069.
    PubMed    


  74. CHEN S, Tao Y, Wang Q, Ren J, et al
    Glucose induced-AKT/mTOR activation accelerates glycolysis and promotes cell survival in acute myeloid leukemia.
    Leuk Res. 2023;128:107059.
    PubMed     Abstract available


  75. CHANTEPIE SP, Mear JB, Briant AR, Vilque JP, et al
    Effect of single-unit transfusion in patients treated for haematological disease including acute leukemia: A multicenter randomized controlled clinical trial.
    Leuk Res. 2023;129:107058.
    PubMed     Abstract available


  76. ILLANGESWARAN RSS, Jebanesan DZP, Sivakumar KK, Vidhyadharan RT, et al
    Chemotherapeutic drugs elicit stemness and metabolic alteration to mediate acquired drug-resistant phenotype in acute myeloid leukemia cell lines.
    Leuk Res. 2023;128:107054.
    PubMed     Abstract available


  77. KILIC GUNES E, Ozkurt ZN, Yildiz S, Ozet G, et al
    Comparison of maintenance regimens in Acute Promyelocytic Leukemia patients.
    Leuk Res. 2023;128:107055.
    PubMed     Abstract available


  78. LAPIETRA G, Limongi MZ, Buffolino S, Nanni M, et al
    Late appearance of JAK2 mutated polycythaemia vera in a patient with typical chronic myeloid leukaemia on imatinib: Speculations about role of therapeutic pressure and of secondary genetic events.
    Leuk Res. 2023;126:107035.
    PubMed    


  79. JAHN J, Diamond B, Hsu J, Montoya S, et al
    Therapy-selected clonal hematopoiesis and its role in myeloid neoplasms.
    Leuk Res. 2023;126:107020.
    PubMed     Abstract available


    February 2023
  80. BATALLER A, Chien KS, Sasaki K, Montalban-Bravo G, et al
    PHF6 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia and acute myeloid leukemia.
    Leuk Res. 2023;127:107044.
    PubMed    


  81. MAURILLO L, Spagnoli A, Candoni A, Papayannidis C, et al
    Comparison between azacitidine and decitabine as front-line therapy in elderly acute myeloid leukemia patients not eligible for intensive chemotherapy.
    Leuk Res. 2023;127:107040.
    PubMed     Abstract available


  82. YANG Z, Liu C, Hu Y, Liu H, et al
    Tyrosine kinase inhibitors combined with venetoclax and azacytidine as an effective therapy for de novo lymphoid blast phase-chronic myeloid leukemia.
    Leuk Res. 2023;127:107039.
    PubMed    


  83. PREMNATH N, Chung SS, Weinberg OK, Ikpefan R, et al
    Clinical and molecular characteristics associated with Vitamin C deficiency in myeloid malignancies; real world data from a prospective cohort.
    Leuk Res. 2023;125:107001.
    PubMed     Abstract available


    January 2023
  84. TARANTINI F, Cumbo C, Zagaria A, Anelli L, et al
    Clonal hematopoiesis onset in chronic myeloid leukemia patients developing an adverse cardiovascular event.
    Leuk Res. 2023;127:107023.
    PubMed     Abstract available


  85. MOHAMMADI F, Rostami G, Hamid M, Shafiei M, et al
    Association of ABCB1, ABCG2 drug transporter polymorphisms and smoking with disease risk and cytogenetic response to imatinib in chronic myeloid leukemia patients.
    Leuk Res. 2023;126:107021.
    PubMed     Abstract available


  86. NABIL R, Abdellateif MS, Gamal H, Hassan NM, et al
    Clinical significance of EVI-1 gene expression and aberrations in patient with de-novo acute myeloid and acute lymphoid leukemia.
    Leuk Res. 2023;126:107019.
    PubMed     Abstract available


  87. OWEN C, Banerji V, Johnson N, Gerrie A, et al
    Canadian evidence-based guideline for frontline treatment of chronic lymphocytic leukemia: 2022 update.
    Leuk Res. 2023;125:107016.
    PubMed     Abstract available


  88. HEEKUK P, Uhlemann AC, Jacobs SS, Mowbray C, et al
    Title: Obesogenic microbial signatures and the development of obesity in childhood acute lymphoblastic leukemia.
    Leuk Res. 2023;126:107017.
    PubMed     Abstract available


  89. DEMINA I, Zerkalenkova E, Semchenkova A, Volchkov E, et al
    Rare case of pediatric trilineal mixed-phenotype acute leukemia with t(11;19)(q23.3;p13)/KMT2A::ELL.
    Leuk Res. 2023;125:107018.
    PubMed    


  90. FUKUDA S, Matsuda N, Shoji T, Onishi C, et al
    The magnitude of CXCR4 signaling regulates resistance to quizartinib in FLT3/ITD(+) cells via RUNX1.
    Leuk Res. 2023;124:106983.
    PubMed     Abstract available


  91. RAMANAN R, Tiong IS, Ivey A, Ong DM, et al
    Cellular distribution of IDH mutations in AML during morphologic remission.
    Leuk Res. 2023;124:106993.
    PubMed     Abstract available


    December 2022
  92. RAMAN HS, Kim SE, DeAngelo DJ, Stevenson KE, et al
    Intensity of induction regimen and outcomes among adults with Ph+ALL undergoing allogeneic hematopoietic stem cell transplantation.
    Leuk Res. 2022;125:107004.
    PubMed     Abstract available


  93. POPOV A, Henze G, Roumiantseva J, Budanov O, et al
    Flow cytometric MRD at the end of consolidation in childhood B-lineage acute lymphoblastic leukemia has significant prognostic value but limited clinical implications: Results of study ALL-MB 2008.
    Leuk Res. 2022;125:106998.
    PubMed    


  94. ZHOU Q, Zhao D, Eladl E, Capo-Chichi JM, et al
    Molecular genetic characterization of Philadelphia chromosome-positive acute myeloid leukemia.
    Leuk Res. 2022;124:107002.
    PubMed     Abstract available


  95. ABEDIN SM, Badar T, Gauger K, Michaelis LC, et al
    Safety and efficacy of pracinostat in combination with gemtuzumab ozogamicin (PraGO) in patients with relapsed/refractory acute myeloid leukemia.
    Leuk Res. 2022;123:106984.
    PubMed    


  96. RAMIA DE CAP M, Wu LP, Pihan GA, Narayanan D, et al
    NPM1 mutations may be associated with adverse outcome in the setting of myeloid neoplasms with complex karyotype.
    Leuk Res. 2022;123:106965.
    PubMed    


  97. GABRA MM, Chow JT, Kim T, Son MH, et al
    A 5-microRNA signature derived from core binding factor-AML is predictive in adult and childhood AML.
    Leuk Res. 2022;123:106968.
    PubMed    


    November 2022
  98. COTTINGHAM AH, Baker LB, Hoffmann ML, Martin CE, et al
    We were in the fight together: The expectations of bereaved caregivers of patients with acute myeloid leukemia from diagnosis to death.
    Leuk Res. 2022;124:106994.
    PubMed     Abstract available


  99. OERTLING E, Fuda F, Koduru P, Chen M, et al
    Distinct mutational and clinicopathologic profiles characterize acute myeloid leukemia with cup-like nuclei.
    Leuk Res. 2022;124:106995.
    PubMed    


  100. KING AC, Derkach A, Weis TM, Stump SE, et al
    Real-world analysis of the safety/tolerability of gilteritinib in combination with mold-active azole prophylaxis.
    Leuk Res. 2022;122:106929.
    PubMed    


    October 2022
  101. POPOV A, Henze G, Roumiantseva J, Budanov O, et al
    A single flow cytometric MRD measurement in children with B-lineage acute lymphocytic leukemia and hyperleukocytosis redefines the requirements of high-risk treatment: Results of the study ALL-MB 2008.
    Leuk Res. 2022;123:106982.
    PubMed    


  102. PARISI R, Cowen EA, Stoll JR, Zhu H, et al
    Dermatologic adverse events associated with IDH inhibitors ivosidenib and enasidenib for the treatment of acute myeloid leukemia.
    Leuk Res. 2022;123:106970.
    PubMed     Abstract available


  103. KAYA Z, Keser E, Atalay E, Kayhan G, et al
    Two distinct syndromic children with T-acute lymphoblastic leukemia: Noonan syndrome and Sotos syndrome.
    Leuk Res. 2022;123:106981.
    PubMed    


  104. GANZEL C, Sun Z, Baslan T, Zhang Y, et al
    Measurable residual disease by flow cytometry in acute myeloid leukemia is prognostic, independent of genomic profiling.
    Leuk Res. 2022;123:106971.
    PubMed     Abstract available


  105. FUJIWARA SI, Murahashi R, Nakashima H, Matsuoka S, et al
    Effect of cumulative daunorubicin dose on cardiotoxicity after allogeneic stem cell transplantation.
    Leuk Res. 2022;121:106951.
    PubMed     Abstract available


  106. LI L, Hu X, Nkwocha J, Sharma K, et al
    Functional role of DNMT1 in the anti-leukemic effects of hypomethylating agents in AML cells.
    Leuk Res. 2022;121:106944.
    PubMed    


  107. NANAA A, He R, Viswanatha D, Nguyen P, et al
    Comparison between GATA2 and DDX41-mutated myeloid neoplasms.
    Leuk Res. 2022;121:106931.
    PubMed    


  108. PODGORNIK H, Sucurovic S, Skerget M, Debeljak M, et al
    Acquired somatic variants confirm the independent development of AML in monozygotic twins with germline CEBPA variant.
    Leuk Res. 2022;121:106933.
    PubMed    


  109. RAINCHWAR S, Halder R, Singh R, Mehta P, et al
    Pneumocystis jirovecii pneumonia [PJP]: An unrecognized concern in AML patients on Venetoclax.
    Leuk Res. 2022;121:106926.
    PubMed     Abstract available


    September 2022
  110. DEFINA M, Lazzarotto D, Guolo F, Minetto P, et al
    Levocarnitine supplementation for asparaginase-induced hepatotoxicity in adult acute lymphoblastic leukemia patients: A multicenter observational study of the campus all group.
    Leuk Res. 2022;122:106963.
    PubMed    


  111. MEENA JP, Pathak N, Gupta AK, Bakhshi S, et al
    Molecular evaluation of gene mutation profiles and copy number variations in pediatric acute myeloid leukemia.
    Leuk Res. 2022;122:106954.
    PubMed     Abstract available


  112. LAN X, Ruminy P, Bohers E, Rainville V, et al
    5' Rapid amplification of cDNA ends (5'RACE): A simpler method to analyze immunoglobulin genes and discover the value of the light chain in chronic lymphocytic leukemia.
    Leuk Res. 2022;123:106952.
    PubMed     Abstract available


  113. MA S, Rosen ST, Winqvist M, Frankfurt O, et al
    Dual targeting fixed duration frontline monoclonal antibody therapy for chronic lymphocytic leukemia: A phase 2 study.
    Leuk Res. 2022;122:106945.
    PubMed     Abstract available


  114. KLINK AJ, Gajra A, Knoth RL, Marshall L, et al
    Real-world clinical outcomes with enasidenib in relapsed or refractory acute myeloid leukemia.
    Leuk Res. 2022;122:106946.
    PubMed     Abstract available


  115. ANGHELINA M, Naughton MJ, Zhao Q, Ruppert AS, et al
    Corrigendum to "Patient-driven research: Initial results from a prospective health-related quality of life study performed at the request of patients living with hairy cell leukemia" [Leuk. Res. 120 (2022) 106919].
    Leuk Res. 2022 Sep 2:106943. doi: 10.1016/j.leukres.2022.106943.
    PubMed    


  116. QI K, Hu X, Yu X, Cheng H, et al
    Targeting cyclin-dependent kinases 4/6 inhibits survival of megakaryoblasts in acute megakaryoblastic leukaemia.
    Leuk Res. 2022;120:106920.
    PubMed     Abstract available


    August 2022
  117. BEWERSDORF JP, Shallis RM, Derkach A, Goldberg AD, et al
    Efficacy of FLT3 and IDH1/2 inhibitors in patients with acute myeloid leukemia previously treated with venetoclax.
    Leuk Res. 2022;122:106942.
    PubMed     Abstract available


  118. GARCIA-VILLASENOR E, Cortes JE, Reyes-Cisneros OA, Fernandez-Gutierrez JA, et al
    Long-term results of the treatment of adolescents and adults with acute lymphoblastic leukemia with a pediatric-inspired regimen delivered on an outpatient basis: A single institution experience.
    Leuk Res. 2022;121:106935.
    PubMed     Abstract available


  119. CHEN H, Xu LP, Zhang XH, Wang Y, et al
    Safety and outcomes of maintenance therapy with third-generation tyrosine kinase inhibitor after allogeneic hematopoietic cell transplantation in Philadelphia chromosome positive acute lymphoblastic leukemia patients with T315I mutation.
    Leuk Res. 2022;121:106930.
    PubMed     Abstract available


  120. DHAKAL P, Lyden E, Joshi U, Pyakuryal A, et al
    Charlson comorbidity index predicts early mortality and overall survival in acute promyelocytic leukemia.
    Leuk Res. 2022;122:106927.
    PubMed    


  121. ORTI G, Garcia-Gutierrez V, Bautista G, Ferrer-Marin F, et al
    Tyrosine kinase inhibitor dose reduction during the management ofaccelerated phase chronic myeloid leukemia.
    Leuk Res. 2022;121:106923.
    PubMed    


  122. MARLEY AR, Ryder JR, Turcotte LM, Spector LG, et al
    Maternal obesity and acute lymphoblastic leukemia risk in offspring: A summary of trends, epidemiological evidence, and possible biological mechanisms.
    Leuk Res. 2022;121:106924.
    PubMed     Abstract available


  123. KOLODRUBIEC J, Kozlowska M, Irga-Jaworska N, Sedek L, et al
    Efficacy of ruxolitinib in acute lymphoblastic leukemia: A systematic review.
    Leuk Res. 2022;121:106925.
    PubMed     Abstract available


    July 2022
  124. ANGHELINA M, Naughton MJ, Zhao Q, Ruppert AS, et al
    Patient-driven research: Initial results from a prospective health-related quality of life study performed at the request of patients living with hairy cell leukemia.
    Leuk Res. 2022;120:106919.
    PubMed     Abstract available


  125. BARKHORDAR M, Kasaeian A, Janbabai G, Mousavi SA, et al
    Outcomes of haploidentical peripheral stem cell transplantation with combination of post-transplant cyclophosphamide (PTCy) and anti-thymocyte globulin (ATG) compared to unrelated donor transplantation in acute myeloid leukemia: A retrospective 10-yea
    Leuk Res. 2022;120:106918.
    PubMed     Abstract available


  126. ZHAO D, Zarif M, Eladl E, Capo-Chichi JM, et al
    NPM1-mutated AML-MRC diagnosed on the basis of history of MDS or MDS/MPN frequently harbours secondary-type mutations and confers inferior outcome compared to AML with mutated NPM1.
    Leuk Res. 2022;118:106869.
    PubMed     Abstract available


  127. CHAUVET P, Nibourel O, Berthon C, Goursaud L, et al
    Resurgence of myeloproliferative neoplasm in patients in remission from blast transformation after treatment with hypomethylating agents.
    Leuk Res. 2022;118:106871.
    PubMed     Abstract available


  128. LIU J, Qin W, Wang B, Wang Z, et al
    PTPN11 mutations in adult acute myeloid leukaemia: Prevalence and clinical implications in the context of NPM1 mutation.
    Leuk Res. 2022;118:106859.
    PubMed     Abstract available


    June 2022
  129. LIPILKIN PV, Kulaeva ED, Mashkina EV
    Prognostic value of ASXL1 mutations in acute myeloid leukemia: A meta-analysis.
    Leuk Res. 2022;120:106910.
    PubMed     Abstract available


  130. GAO X, Fan S, Zhang X
    MiR-1306-5p promotes cell proliferation and inhibits cell apoptosis in acute myeloid leukemia by downregulating PHF6 expression.
    Leuk Res. 2022;120:106906.
    PubMed     Abstract available


  131. CHOJECKI AL, Arnall J, Boselli D, Patel R, et al
    Outcomes and hospitalization patterns of patients with acute myelogenous leukemia treated with frontline CPX-351 or HMA/venetoclax.
    Leuk Res. 2022;119:106904.
    PubMed    


  132. DUMAS PY, Bertoli S, Bonmati C, Carre M, et al
    Characteristics and clinical outcomes of SARS-CoV-2 infection in adult patients with acute leukemia in France.
    Leuk Res. 2022;120:106901.
    PubMed    


  133. FRISCH A, Aumann S, Zuckerman T, Leiba R, et al
    Re-induction versus salvage for D14-resiudal acute myeloid leukemia: A retrospective multi-center study.
    Leuk Res. 2022;119:106902.
    PubMed     Abstract available


  134. OTHMAN T, Moskoff BN, Ho G, Tenold ME, et al
    Clinical experience with frontline Hyper-CVAD-based regimens, including Hyper-CVAD plus ponatinib, in patients with acute lymphoblastic leukemia treated at a comprehensive cancer center.
    Leuk Res. 2022;119:106885.
    PubMed     Abstract available


  135. TATARIAN J, Byrd K, Male HJ, Lin TL, et al
    Central nervous system involvement in adult acute myeloid leukemia patients.
    Leuk Res. 2022;118:106882.
    PubMed    


  136. HASHIMOTO H, Gungor D, Krickeberg N, Schmitt J, et al
    TH1 cytokines induce senescence in AML.
    Leuk Res. 2022;117:106842.
    PubMed     Abstract available


    May 2022
  137. KIM K, Bazinet A, Loghavi S, Konopleva M, et al
    Major clinical response in a patient with leukemia cutis treated with the bromodomain inhibitor PLX51107 and azacitidine.
    Leuk Res. 2022;119:106884.
    PubMed    


  138. GOSWAMI S, Chiang CL, Zapolnik K, Nunes J, et al
    ROR1 targeted immunoliposomal delivery of OSU-2S shows selective cytotoxicity in t(1;19)(q23;p13) translocated B-cell acute lymphoblastic leukemia.
    Leuk Res. 2022;118:106872.
    PubMed    


  139. STEIDL C, Aroldi A, Mologni L, Crespiatico I, et al
    Validation of a new NGS-based myeloid panel in acute myeloid leukemia: A single-center experience.
    Leuk Res. 2022;118:106861.
    PubMed     Abstract available


  140. TASHAKORI M, Wang W, Kadia TM, Daver NG, et al
    Differential characteristics of TP53 alterations in pure erythroid leukemia arising after exposure to cytotoxic therapy.
    Leuk Res. 2022;118:106860.
    PubMed     Abstract available


  141. KIM T, Ahn JS, Son MH, Novitzky-Basso I, et al
    Genetic changes during leukemic transformation to secondary acute myeloid leukemia from myeloproliferative neoplasms.
    Leuk Res. 2022;118:106858.
    PubMed     Abstract available


  142. KARBALIVAND M, Almada LL, Ansell SM, Fernandez-Zapico ME, et al
    MLL1 inhibition reduces IgM levels in Waldenstrom macroglobulinemia.
    Leuk Res. 2022;116:106841.
    PubMed     Abstract available


  143. NORVILAS R, Batiuskaite R, Dirse V, Semaskeviciene R, et al
    Population-based targeted RNA sequencing reveals novel disease-related gene fusions in pediatric and adult T-ALL.
    Leuk Res. 2022;116:106825.
    PubMed     Abstract available


    April 2022
  144. ARORA S, Zainaldin C, Bathini S, Gupta U, et al
    Tumor lysis syndrome and infectious complications during treatment with venetoclax combined with azacitidine or decitabine in patients with acute myeloid leukemia.
    Leuk Res. 2022;117:106844.
    PubMed     Abstract available


  145. BAI H, Zhang Q, Zhang S, Wang J, et al
    Multiple cells of origin in common with various types of mouse N-Myc acute leukemia.
    Leuk Res. 2022;117:106843.
    PubMed     Abstract available


    March 2022
  146. NGUYEN PC, Donati V, Vassili C, Grigg AP, et al
    Real-world tolerability of venetoclax-based maintenance therapy with azole antifungal prophylaxis for acute myeloid leukemia in remission.
    Leuk Res. 2022 Mar 27:106837. doi: 10.1016/j.leukres.2022.106837.
    PubMed    


  147. SHEHATA AMF, Gohar SF, Muharram NM, Eldin SMK, et al
    LncRNA CCAT2 expression at diagnosis predicts imatinib response in chronic phase chronic myeloid leukemia patients.
    Leuk Res. 2022;116:106838.
    PubMed     Abstract available


  148. TRIGUERO A, Xicoy B, Zamora L, Jimenez MJ, et al
    Response to azacitidine in patients with chronic myelomonocytic leukemia according to overlap myelodysplastic/myeloproliferative neoplasms criteria.
    Leuk Res. 2022;116:106836.
    PubMed     Abstract available


  149. JELLOUL FZ, Yang R, Garces S, Kanagal-Shamanna R, et al
    Landscape of NOTCH1 mutations and co-occurring biomarker alterations in chronic lymphocytic leukemia.
    Leuk Res. 2022;116:106827.
    PubMed     Abstract available


  150. BHREATHNACH U, Doherty D, Murphy K, Flynn CM, et al
    Monitoring KAT6A-CREBBP measurable residual disease in t(8;16) therapy-related acute myeloid leukemia.
    Leuk Res. 2022;116:106823.
    PubMed    


  151. KAMATH-LOEB AS, Shen JC, Schmitt MW, Kohrn BF, et al
    Accurate detection of subclonal variants in paired diagnosis-relapse acute myeloid leukemia samples by next generation Duplex Sequencing.
    Leuk Res. 2022;115:106822.
    PubMed     Abstract available


  152. HERNANDEZ-BOLUDA JC, Martinez-Cuadron D, Pereira A, Rodriguez-Veiga R, et al
    Acute leukemia arising from myeloproliferative or myelodysplastic/myeloproliferative neoplasms: A series of 372 patients from the PETHEMA AML registry.
    Leuk Res. 2022;115:106821.
    PubMed     Abstract available


  153. WANG X, Bajpai AK, Gu Q, Centeno A, et al
    A systems genetics approach delineates the role of Bcl2 in leukemia pathogenesis.
    Leuk Res. 2022;114:106804.
    PubMed     Abstract available


    February 2022
  154. DE BELLIS E, Imbergamo S, Candoni A, Lico A, et al
    Corrigendum to "Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience" [Leukemia Res. 114 (March 2022) 106803].
    Leuk Res. 2022 Feb 23:106811. doi: 10.1016/j.leukres.2022.106811.
    PubMed    


  155. ROSTAMI M, Kharajo RS, Parsa-Kondelaji M, Ayatollahi H, et al
    Altered expression of NEAT1 variants and P53, PTEN, and BCL-2 genes in patients with acute myeloid leukemia.
    Leuk Res. 2022;115:106807.
    PubMed     Abstract available


  156. NUHOGLU KANTARCI E, Eskazan AE
    Gilteritinib in the management of acute myeloid leukemia: Current evidence and future directions.
    Leuk Res. 2022;114:106808.
    PubMed     Abstract available


  157. DE BELLIS E, Imbergamo S, Candoni A, Lico A, et al
    Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience.
    Leuk Res. 2022;114:106803.
    PubMed     Abstract available


  158. KUSNE Y, Xie Z, Patnaik MM
    Clonal hematopoiesis: Molecular and clinical implications.
    Leuk Res. 2022;113:106787.
    PubMed     Abstract available


  159. CHORNENKI NLJ, Siegal DM, Qamar K, Woolgar S, et al
    Characterizing Frailty In Myeloproliferative Neoplasms: results from the ORCHID study.
    Leuk Res. 2022;113:106788.
    PubMed    


    January 2022
  160. PARK H, Kang S, Kim I, Kim S, et al
    The association of genetic alterations with response rate in newly diagnosed chronic myeloid leukemia patients.
    Leuk Res. 2022;114:106791.
    PubMed     Abstract available


  161. THOMAS JW, Jamy O, Shah MV, Vachhani P, et al
    Risk of mortality and second malignancies in primary myelofibrosis before and after ruxolitinib approval.
    Leuk Res. 2022;112:106770.
    PubMed     Abstract available


  162. SORIGUE M, Arenillas L, Xicoy B, Andrade-Campos M, et al
    Monocyte subset distribution in myeloproliferative and myelodysplastic/myeloproliferative neoplasms with monocytosis.
    Leuk Res. 2022;112:106771.
    PubMed    


  163. ALAYED K, Meyerson HJ
    Decreased CD177(pos) neutrophils in myeloid neoplasms is associated with NPM1, RUNX1, TET2, and U2AF1 S34F mutations.
    Leuk Res. 2022;112:106752.
    PubMed     Abstract available


  164. PARKER C, Ayton D, Zomer E, Liew D, et al
    Do patients with haematological malignancies suffer financial burden? A cross-sectional study of patients seeking care through a publicly funded healthcare system.
    Leuk Res. 2022;112:106748.
    PubMed     Abstract available


    December 2021
  165. SHERBAN A, Raanani P, Gurion R, Wolach O, et al
    Maintenance therapy with hypomethylating agents for patients with acute myeloid leukemia in first remission not eligible for allogeneic hematopoietic cell transplantation: A systematic review and meta-analysis.
    Leuk Res. 2021;113:106773.
    PubMed     Abstract available


  166. WEBSTER JA, Robinson TM, Blackford AL, Warlick E, et al
    A randomized, phase II trial of adjuvant immunotherapy with durable TKI-free survival in patients with chronic phase CML.
    Leuk Res. 2021;111:106737.
    PubMed     Abstract available


  167. GAJZER D, Logothetis CN, Sallman DA, Calon G, et al
    MYC overexpression is associated with an early disease progression from MDS to AML.
    Leuk Res. 2021;111:106733.
    PubMed     Abstract available


  168. OBENG-KUSI M, MacDonald K, van Lierde MA, Lee CS, et al
    No margin for non-adherence: Probabilistic kaplan-meier modeling of imatinib non-adherence and treatment response in CML (ADAGIO study).
    Leuk Res. 2021;111:106734.
    PubMed     Abstract available


  169. KOTA V, Brummendorf TH, Gambacorti-Passerini C, Lipton JH, et al
    Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosomepositive leukemias.
    Leuk Res. 2021;111:106690.
    PubMed     Abstract available


  170. BAYRAK AG, Daglar Aday A, Yavuz AS, Nalcaci M, et al
    Overview of clinical and genetic features of CML patients with variant Philadelphia translocations involving chromosome 7: A case series.
    Leuk Res. 2021;111:106725.
    PubMed     Abstract available


  171. MCBRIDE A, Daniel S, Driessen MT, Szende A, et al
    Assessment of rituximab-abbs, a biosimilar, and rituximab outcomes in patients with CLL or NHL: A real-world UK study.
    Leuk Res. 2021;111:106671.
    PubMed     Abstract available


  172. BORSKY M, Hrabcakova V, Novotna J, Brychtova Y, et al
    Rituximab induces rapid blood repopulation by CLL cells mediated through their release from immune niches and complement exhaustion.
    Leuk Res. 2021;111:106684.
    PubMed     Abstract available


    November 2021
  173. KAIVERS J, Peters J, Rautenberg C, Schroeder T, et al
    The WHO 2016 diagnostic criteria for Acute Myeloid leukemia with myelodysplasia related changes (AML-MRC) produce a very heterogeneous entity: A retrospective analysis of the FAB subtype RAEB-T.
    Leuk Res. 2021;112:106757.
    PubMed     Abstract available


  174. PERMIKIN Z, Popov A, Verzhbitskaya T, Riger T, et al
    Lineage switch to acute myeloid leukemia during induction chemotherapy for early T-cell precursor acute lymphoblastic leukemia with the translocation t(6;11)(q27;q23)/KMT2A-AFDN: A case report.
    Leuk Res. 2021;112:106758.
    PubMed    


  175. SREEDHARANUNNI S, Jamwal M, Balakrishnan A, Aravindan AV, et al
    Chronic eosinophilic leukemia with recurrent STAT5B N642H mutation-An entity with features of myelodysplastic syndrome/ myeloproliferative neoplasm overlap.
    Leuk Res. 2021;112:106753.
    PubMed    


  176. CIROVIC A, Cirovic A
    Iron deficiency as promoter of heavy metals-induced acute myeloid leukemia.
    Leuk Res. 2021;112:106755.
    PubMed     Abstract available


  177. NORSKOV KH, Fridthjof K, Kampmann P, Dunweber A, et al
    A national Danish proof of concept on feasibility and safety of home -based intensive chemotherapy in patients with acute myeloid leukemia.
    Leuk Res. 2021;112:106756.
    PubMed     Abstract available


  178. KEE KM, Kim SH, Yang SY, Shin JU, et al
    Comparison of 3-month cytogenetic and molecular assays for early assessment of long-term clinical impact after BCR-ABL1 tyrosine kinase inhibitor treatment in chronic myeloid leukemia.
    Leuk Res. 2021;112:106754.
    PubMed     Abstract available


  179. MIRFAKHRAIE R, Noorazar L, Mohammadian M, Hajifathali A, et al
    Treatment Failure in Acute Myeloid Leukemia: Focus on the Role of Extracellular Vesicles.
    Leuk Res. 2021;112:106751.
    PubMed     Abstract available


  180. LIESVELD JL, Baran A, Azadniv M, Misch H, et al
    A phase II study of sequential decitabine and rapamycin in acute myelogenous leukemia.
    Leuk Res. 2021;112:106749.
    PubMed     Abstract available


  181. GALASSI L, Colasante C, Bettelli F, Gilioli A, et al
    Pre-existing cytopenia heralding de novo acute myeloid leukemia: Uncommon presentation of NPM1-mutated AML in a single-center study.
    Leuk Res. 2021;111:106747.
    PubMed    


  182. HUSELTON E, Rettig MP, Campbell K, Cashen AF, et al
    Combination of dociparstat sodium (DSTAT), a CXCL12/CXCR4 inhibitor, with azacitidine for the treatment of hypomethylating agent refractory AML and MDS.
    Leuk Res. 2021;110:106713.
    PubMed     Abstract available


  183. WONG R, Nguyen A, Wang X, Chong L, et al
    Improved resolution of phenotypic subsets in human T-ALL by incorporation of RNA-seq based developmental profiling.
    Leuk Res. 2021;110:106712.
    PubMed    


  184. AN L, Li X, Yang J
    MicroRNA-211 attenuates cell proliferation in T-cell lymphoblastic lymphoma through targeting TCF12.
    Leuk Res. 2021;110:106653.
    PubMed     Abstract available


    October 2021
  185. LUGER SM, Wang VX, Rowe JM, Litzow MR, et al
    Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial.
    Leuk Res. 2021;111:106736.
    PubMed     Abstract available


  186. CHOW S, Tang K, Al-Abri M, Hall V, et al
    RUNX1 mutations correlate with response to venetoclax combination therapies in relapsed/refractory acute myeloid leukemia.
    Leuk Res. 2021;111:106735.
    PubMed    


  187. KANNAN KK, Vellanki P, Isom S, Tawfik B, et al
    Re-induction therapy in adult patients with acute myeloid leukemia with
    Leuk Res. 2021;111:106731.
    PubMed    


  188. BAGHAEI VAJI F, Boroumand Nasr A, Rezvani A, Ayatollahi H, et al
    Prognostic significance of ATM mutations in chronic lymphocytic leukemia: A meta-analysis.
    Leuk Res. 2021;111:106729.
    PubMed     Abstract available


  189. KALEKA G, Schiller G
    Immunotherapy for Acute Myeloid Leukemia: Allogeneic hematopoietic cell transplantation is here to stay.
    Leuk Res. 2021;112:106732.
    PubMed     Abstract available


  190. PADMAKUMAR D, Chandraprabha VR, Gopinath P, Vimala Devi ART, et al
    A concise review on the molecular genetics of acute myeloid leukemia.
    Leuk Res. 2021;111:106727.
    PubMed     Abstract available


  191. PARK H, Kim I, Kim HJ, Shin DY, et al
    Ultra-deep sequencing mutation analysis of the BCR/ABL1 kinase domain in newly diagnosed chronic myeloid leukemia patients.
    Leuk Res. 2021;111:106728.
    PubMed     Abstract available


  192. MARTINEZ-VERBO L, Estrada N, Cabezon M, Palomo L, et al
    Mutational profile and relative telomere length in Chronic Myelomonocytic Leukemia subgroups according to the 2016 World Health Organization classification.
    Leuk Res. 2021;111:106726.
    PubMed    


  193. LIM K, Thompson-Peach C, Thomas D
    Neonatal heel prick mass spectrometry identifies metabolic predictors of AML latency.
    Leuk Res. 2021;109:106644.
    PubMed     Abstract available


    September 2021
  194. GOKCEN S, Bagriacik EU, Kayhan H, Yagci M, et al
    Immunomolecular evaluation of dihydroartemisinin effects on apoptosis in chronic lymphocytic leukemia cell lines.
    Leuk Res. 2021;110:106702.
    PubMed     Abstract available


  195. ESFANDBOD M, Enshaei M, Monzavi SM, Kabootari M, et al
    Radiation-Free myeloablative allogeneic hematopoietic stem cell transplantation for adult acute lymphoblastic leukemia: A comparison of outcomes between patients with and without central nervous system involvement.
    Leuk Res. 2021;111:106703.
    PubMed     Abstract available


  196. CARRAWAY HE, Sawalha Y, Gojo I, Lee MJ, et al
    Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease) acute lymphoblastic leukemia or biphenotypic leukem
    Leuk Res. 2021;110:106707.
    PubMed     Abstract available


  197. DU X, Liu H, Yang C, Shi X, et al
    LncRNA landscape analysis identified LncRNA LEF-AS1 as an oncogene that upregulates LEF1 and promotes survival in chronic lymphocytic leukemia.
    Leuk Res. 2021;110:106706.
    PubMed     Abstract available


  198. ALVAREZ N, Rodriguez-Garcia A, Morales ML, Gutierrez M, et al
    Clonal hematopoiesis-defining mutations have no impact on the development of thrombosis in a cohort of patients with myeloid pathology.
    Leuk Res. 2021;108:106613.
    PubMed    


  199. ALEISSA MM, Alshehri BS, Gonzalez-Bocco IH, McDonnell AM, et al
    Triazole antifungal use for prophylaxis and treatment of invasive fungal diseases for patients receiving gilteritinib.
    Leuk Res. 2021;108:106610.
    PubMed     Abstract available


  200. LINCH DC, Hills RK, Gilkes A, Burnett AK, et al
    Additional impact of mutational genotype on prognostic determination in resistant and relapsed acute myeloid leukaemia.
    Leuk Res. 2021;108:106553.
    PubMed     Abstract available


    August 2021
  201. YU J, Du Y, Jalil A, Ahmed Z, et al
    Mutational profiling of myeloid neoplasms associated genes may aid the diagnosis of acute myeloid leukemia with myelodysplasia-related changes.
    Leuk Res. 2021;110:106701.
    PubMed     Abstract available


  202. ABRAMENKO I, Bilous N, Chumak A, Kryachok I, et al
    The signs of negative selection in IGHV framework regions are associated with worse overall survival of chronic lymphocytic leukemia patients.
    Leuk Res. 2021;110:106686.
    PubMed     Abstract available


  203. DARASKEVICIUS J, Everatt V, Vaitekenaite V, Ringeleviciute U, et al
    Venetoclax in combination with low dose Cytarabine and Actinomycin D for primary refractory acute myeloid leukemia patients failing intensive chemotherapy.
    Leuk Res. 2021;111:106692.
    PubMed    


  204. RAHIMI Z, Ghorbani Z, Motamed H, Jalilian N, et al
    Aberrant expression profile of miR-32, miR-98 and miR-374 in chronic lymphocytic leukemia.
    Leuk Res. 2021;111:106691.
    PubMed     Abstract available


  205. YOUNG PE, Kanagal-Shamanna R, Hu S, Tang G, et al
    Chronic myeloid leukemia, BCR-ABL1-positive, carrying NPM1 mutation - First case series from a single institution.
    Leuk Res. 2021;111:106685.
    PubMed    


  206. GOWIN K, Skerget S, Keats JJ, Mikhael J, et al
    Plasma cell leukemia: A review of the molecular classification, diagnosis, and evidenced-based treatment.
    Leuk Res. 2021;111:106687.
    PubMed     Abstract available


  207. GUPTA SK, Bakhshi S, Kamal VK, Gupta R, et al
    Proposal and clinical application of molecular genetic risk scoring system, "MRplus", for BCR-ABL1 negative pediatric B-cell acute lymphoblastic leukemia- report from a single centre.
    Leuk Res. 2021;111:106683.
    PubMed     Abstract available


    July 2021
  208. PLESA A, Roumier C, Gutrin J, Larcher MV, et al
    Measurable residual disease including AML leukemia stem cell flow evaluation of CPX-351 therapy by multi-parameter flow cytometry.
    Leuk Res. 2021;111:106673.
    PubMed    


  209. MA CE, Ghosh S, Leyshon C, Blosser N, et al
    Clinical outcome of chronic myeloid leukemia patients who switch from first-line therapy with a second generation tyrosine kinase inhibitor to an alternative TKI.
    Leuk Res. 2021;111:106674.
    PubMed     Abstract available


  210. ALSHEMMARI SH, Hamdah A, Pandita R, Kunhikrishnan A, et al
    Chronic lymphocytic leukemia in a young population.
    Leuk Res. 2021;110:106668.
    PubMed     Abstract available


  211. SILVA WF, Silverio A, Duarte BKL, Aguiar TF, et al
    Philadelphia-positive B-lymphoblastic leukemia in a middle-income country - A real-world multicenter cohort.
    Leuk Res. 2021;110:106666.
    PubMed     Abstract available


  212. HARRIS RA, Stevens JM, Pickering DL, Althof PA, et al
    Frequency, variations, and prognostic implications of chromosome 14q32 deletions in chronic lymphocytic leukemia.
    Leuk Res. 2021;110:106665.
    PubMed     Abstract available


  213. SMITH MR, Cronin JF, Weiss RF
    Alternative strategies for optimizing treatment of chronic lymphocytic leukemia with complex clonal architecture.
    Leuk Res. 2021;110:106663.
    PubMed     Abstract available


  214. DEMINA I, Zerkalenkova E, Zhogov V, Lagoyko S, et al
    The use of additional immunophenotypic criteria for the differential diagnosis of Burkitt lymphoma/leukemia: An exemplary case report.
    Leuk Res. 2021;110:106662.
    PubMed    


  215. IBRAHIM M, Chen R, Vegel A, Panse K, et al
    Treatment of myeloid sarcoma without bone marrow involvement with gemtuzumab ozogamicin-containing regimen.
    Leuk Res. 2021;106:106583.
    PubMed    


  216. GLASS JL, Derkach A, Hilden P, King A, et al
    Arsenic trioxide therapy predisposes to herpes zoster reactivation despite minimally myelosuppressive therapy.
    Leuk Res. 2021;106:106569.
    PubMed     Abstract available


    June 2021
  217. KONDYLI M, Tremblay DE, Rezgui A, Serfaty SA, et al
    Human Leucocyte Antigen alleles associated with asparaginase hypersensitivity in childhood Acute Lymphoblastic Leukemia patients treated with Pegylated asparaginase within Dana Farber Cancer Institute treatment protocols.
    Leuk Res. 2021;109:106650.
    PubMed    


  218. CHENG L, Zeng S, Yan D, Tu L, et al
    Cytarabine and EIP co-administration synergistically reduces viability of acute lymphoblastic leukemia cells with high ERG expression.
    Leuk Res. 2021;109:106649.
    PubMed     Abstract available


  219. ZHANG Y, Feng S
    The impact of tyrosine kinase inhibitors on allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Leuk Res. 2021;109:106647.
    PubMed     Abstract available


  220. ZAMANI A, Fattahi Dolatabadi N, Houshmand M, Nabavizadeh N, et al
    miR-324-3p and miR-508-5p expression levels could serve as potential diagnostic and multidrug-resistant biomarkers in childhood acute lymphoblastic leukemia.
    Leuk Res. 2021;109:106643.
    PubMed     Abstract available


  221. GUPTA SK, Singh P, Chhabra R, Verma M, et al
    Novel pharmacological approach for the prevention of multidrug resistance (MDR) in a human leukemia cell line.
    Leuk Res. 2021;109:106641.
    PubMed     Abstract available


  222. HUNTER AM, Al Ali N, Mai A, Shah S, et al
    Leukocytosis is associated with end organ damage and mortality in chronic myelomonocytic leukemia and can be mitigated by cytoreductive therapy.
    Leuk Res. 2021;109:106640.
    PubMed    


  223. GENESCA E, Morgades M, Gonzalez-Gil C, Fuster-Tormo F, et al
    Adverse prognostic impact of complex karyotype (>/=3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL).
    Leuk Res. 2021;109:106612.
    PubMed     Abstract available


  224. SONG J, Shang B, Pei Y, Shi M, et al
    A higher percentage of leukemic blasts with vacuoles predicts unfavorable outcomes in patients with acute myeloid leukemia.
    Leuk Res. 2021;109:106638.
    PubMed     Abstract available


  225. ISHDORJ G, Nugent Z, Squires M, Kost S, et al
    Rapid improvement in symptoms and physical function following ibrutinib initiation in chronic lymphocytic leukemia and the associated changes in plasma cytokines.
    Leuk Res. 2021;109:106628.
    PubMed     Abstract available


  226. CHANDRA SEKARAN U, Grove CS
    Prognostic factors and their importance in relapsed and refractory AML: Comments on "Additional impact of mutational genotype on prognostic determination in resistant and relapsed acute myeloid leukaemia" by Linch et al.
    Leuk Res. 2021;105:106572.
    PubMed    


  227. MIYAUCHI J, Kawaguchi H
    The in vitro effects of hepatoblastoma cells on the growth and differentiation of blasts in transient abnormal myelopoiesis associated with Down syndrome.
    Leuk Res. 2021;105:106570.
    PubMed     Abstract available


    May 2021
  228. YASUDA S, Najima Y, Konishi T, Yamada Y, et al
    Outcome of allogeneic hematopoietic stem cell transplantation for T-cell lymphoblastic leukemia/lymphoma: A single-center study.
    Leuk Res. 2021;108:106627.
    PubMed     Abstract available


  229. TANG Z, Kanagal-Shamanna R, Tang G, Patel K, et al
    Analytical and clinical performance of chromosomal microarrays compared with FISH panel and conventional karyotyping in patients with chronic lymphocytic leukemia.
    Leuk Res. 2021;108:106616.
    PubMed     Abstract available


  230. FIEGLE E, Crysandt M, Bouillon AS, Silling G, et al
    Successful allogeneic stem cell transplantation of a patient with Werner syndrome and acute myeloid leukemia.
    Leuk Res. 2021 May 5:106609. doi: 10.1016/j.leukres.2021.106609.
    PubMed    


  231. ALI H, Salhotra A, Stein AS, Nakamura R, et al
    Efficacy of blinatumomab for MRD relapse in ALL post allogenic HCT.
    Leuk Res. 2021;104:106579.
    PubMed    


  232. ETIENNE G, Rea D, Coiteux V, Guerci-Bresler A, et al
    Ponatinib long-term follow-up of efficacy and safety in CP-CML patients in real world settings in France: The POST-PACE study.
    Leuk Res. 2021;104:106541.
    PubMed    


    April 2021
  233. HOCH REE, Coser VM, Santos IS, de Souza APD, et al
    Lymphoid markers predict prognosis of pediatric and adolescent acute myeloid leukemia.
    Leuk Res. 2021;107:106603.
    PubMed     Abstract available


  234. HELALY NA, Esheba NE, Ammo DEA, Elwan NM, et al
    High Bax/Bcl-2 ratio is associated with good prognosis and better survival in patients with B cell chronic lymphocytic leukemia.
    Leuk Res. 2021;107:106604.
    PubMed     Abstract available


  235. SPEROTTO A, Gottardi M, Candoni A, Toffoletti E, et al
    WT1 - Gene expression driven pre-emptive treatment with decitabine for molecular relapse of acute myeloid leukemia after allogeneic stem cell transplant.
    Leuk Res. 2021;108:106587.
    PubMed    


  236. VACHHANI P, Baron J, Freyer CW, Miller A, et al
    A phase 2 trial of single low doses of rasburicase for treatment of hyperuricemia in adult patients with acute leukemia.
    Leuk Res. 2021;107:106588.
    PubMed     Abstract available


  237. CHEN P, Redd L, Schmidt Y, Koduru P, et al
    MYC protein expression does not correlate with MYC abnormalities detected by FISH but predicts an unfavorable prognosis in de novo acute myeloid leukemia.
    Leuk Res. 2021;106:106584.
    PubMed     Abstract available


  238. PETRICK L, Imani P, Perttula K, Yano Y, et al
    Untargeted metabolomics of newborn dried blood spots reveals sex-specific associations with pediatric acute myeloid leukemia.
    Leuk Res. 2021;106:106585.
    PubMed     Abstract available


  239. GARCIA JS, Swords RT, Roboz GJ, Jacoby MA, et al
    Corrigendum to "A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival" [Leukemia Res. 104 March (2021)].
    Leuk Res. 2021 Apr 22:106581. doi: 10.1016/j.leukres.2021.106581.
    PubMed    


  240. KRISTENSEN D, Nielsen LB, Roug AS, Kristensen TC, et al
    The prognostic impact of anthropometrics in acute myeloid leukemia treated with intensive chemotherapy - A Danish nationwide cohort study.
    Leuk Res. 2021;106:106567.
    PubMed    


  241. KIM YJ, Jung SH, Hur EH, Choi EJ, et al
    Clinical implications of copy number alteration detection using panel-based next-generation sequencing data in myelodysplastic syndrome.
    Leuk Res. 2021;103:106540.
    PubMed     Abstract available


    March 2021
  242. PARK S, Choi EJ, Lee H, Jo DY, et al
    Treatment-free remission of chronic myeloid leukemia in real-world practice by the detection limit of MR4.3.
    Leuk Res. 2021;105:106578.
    PubMed     Abstract available


  243. MUUS P, Langemeijer S, van Bijnen S, Blijlevens N, et al
    A phase I clinical trial to study the safety of treatment with tipifarnib combined with bortezomib in patients with advanced stages of myelodysplastic syndrome and oligoblastic acute myeloid leukemia.
    Leuk Res. 2021;105:106573.
    PubMed     Abstract available


  244. ROBAK E, Jesionek-Kupnicka D, Iskierka-Jazdzewska E, Janus A, et al
    Cutaneous leukocytoclastic vasculitis at diagnosis of hairy cell leukemia successfully treated with vemurafenib and rituximab.
    Leuk Res. 2021;104:106571.
    PubMed    


  245. MOHTY R, Massoud R, Chakhachiro Z, Mahfouz R, et al
    Risk adapted therapeutic strategy in newly diagnosed acute myeloid leukemia: Refining the outcomes of ELN 2017 intermediate-risk patients.
    Leuk Res. 2021;105:106568.
    PubMed     Abstract available


  246. NI J, Hong J, Li Q, Zeng Q, et al
    Long non-coding RNA CRNDE suppressing cell proliferation is regulated by DNA methylation in chronic lymphocytic leukemia.
    Leuk Res. 2021;105:106564.
    PubMed     Abstract available


  247. OZKAN T, Hekmatshoar Y, Karabay AZ, Koc A, et al
    Assessment of azithromycin as an anticancer agent for treatment of imatinib sensitive and resistant CML cells.
    Leuk Res. 2021;102:106523.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.